BACKGROUND/OBJECTIVES: Behavioral problems in individuals with Alzheimer's disease (AD) impose major management challenges. Current prevention strategies are anchored to cognitive outcomes, but behavioral outcomes may provide another, clinically relevant opportunity for preemptive therapy. We sought to determine whether personality changes that predispose to behavioral disorders arise during the transition from preclinical AD to mild cognitive impairment (MCI). DESIGN: Longitudinal observational cohort study. SETTING: Academic medical center. PARTICIPANTS: Members of an apolipoprotein E (APOE) ɛ4 genetically enriched cohort of Maricopa County residents who were neuropsychiatrically healthy at entry (N = 277). Over a mean interval of 7 years, 25 who developed MCI and had the Neuroticism, Extraversion, and Openness Personality Inventory-Revised (NEO-PI-R) before and during the MCI transition epoch were compared with 252 nontransitioners also with serial NEO-PI-R administrations. INTERVENTION: Longitudinal administration of the NEO-PI-R and neuropsychological test battery. MEASUREMENTS: Change in NEO-PI-R factor scores (neuroticism, extraversion, openness, agreeableness, conscientiousness) from entry to the epoch of MCI diagnosis or an equivalent follow-up duration in nontransitioners. RESULTS: NEO-PI-R neuroticism T-scores increased significantly more in MCI transitioners than in nontransitioners (mean 2.9, 95% confidence interval (CI) = 0.9-4.9 vs 0, 95% CI = À0.7-0.7, P = .02), and openness decreased more in MCI transitioners than in nontransitioners (À4.8, 95% CI = À7.3 to À2.4 vs À1.0, 95% CI = À1.6 to
C
ognitive loss is the most widely recognized consequence of Alzheimer's disease (AD) and is the defining feature of its symptomatic onset at the stage of mild cognitive impairment (MCI), 1 yet behavioral problems may be the most troubling aspect of dementia care. [2] [3] [4] [5] Analogous to the mild cognitive decline that heralds the symptomatic onset of AD and anticipates the inexorable intellectual decline that subsequently undermines functional capacity, behavioral changes might also begin early, even perhaps with the transition from the presymptomatic to the MCI stage, anticipating the disruptive behaviors that overburden caregivers and prompt medical intervention.
Behavioral problems are often attributed to, or even equated with, a change in an individual's personality, but a distinction should be drawn between them. Personality describes a tendency toward a certain reaction or behavior, not the reaction or behavior itself. Although people change their behaviors in response to varied situations, personality remains stable. 6 For example, a stress-prone individual may feel highly stressed driving in traffic yet feel no stress while watching television, whereas an actively depressed person will be depressed regardless of whether they are driving or watching television. Studies seeking to address the way in which AD affects personality have documented an informant's (typically a spousal caregiver) impressions of how personality changed from the premorbid to the dementia state, but reliance on a proxy's recollection of what an individual with dementia was like before the onset of dementia and confusing the consequence that is the impaired behavior of an individual with frank dementia with earlier true personality changes that predispose to subsequent behavioral disruption limit these studies. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] If personality begins to change as early as the preclinical or MCI stage of AD, then personality assessment might be a way to identify individuals who are at risk of future behavioral problems possibly facilitating earlier (and potentially more benign) intervention, but existing data are limited. 20, 21 To address this need and overcome prior limitations, we have been prospectively administering the Neuroticism, Extraversion, and Openness Personality Inventory-Revised (NEO-PI-R) 22 to members of the Arizona apolipoprotein E (APOE) cohort who are cognitively normal and able to complete their own personality questionnaires to determine whether personality changes during the transition from presymptomatic AD to the earliest symptomatic state (incident MCI).
METHODS

Subjects
From January 1, 1994, through December 31, 2016, cognitively normal residents of Maricopa County aged 21 and older recruited through local media ads underwent APOE genotyping and longitudinal neuropsychological assessment every 2 years. Determination of APOE genotype was performed using TaQMan single nucleotide polymorphism assays.
All identified ɛ4 homozygotes (HMZ) were matched according to age, sex, and education to one ɛ4 heterozygote (HTZ; all with the ɛ3/4 genotype) and two ɛ4 noncarriers. Many additional heterozygous persons and noncarriers who were otherwise eligible for enrollment were also recruited so that roughly half of the cohort represents matched quartos, and the remaining members were not matched but otherwise fulfilled entry criteria. Each participant had screening tests that included a medical history, neurological examination, Folstein Mini-Mental State Examination (MMSE), Hamilton Depression Rating Scale (Ham-D), Functional Activities Questionnaire (FAQ), instrumental activities of daily living (IADLs), and Structured Psychiatric Interview for the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. We excluded anyone with potentially confounding medical, neurological, or psychiatric problems (essentially any condition that might adversely affect cognitive abilities such as end-stage organ disease, stroke, or active major depression). None met published criteria for MCI, 1 AD, 23 other forms of dementia, or major depressive disorder. 24 Entry criteria included scores of at least 27 on the MMSE (with at least 1 of 3 on the recall subtest), 10 or less on the Ham-D, and perfect scores on the FAQ and IADL. All individuals provided written, informed consent to participate in the study and have the results of the APOE test withheld from them, which the Mayo Clinic institutional review board approved.
A neurologist (RJC) and neuropsychologist (DECL) reviewed data at each visit for indications of cognitive impairment. Amnestic MCI was diagnosed in individuals who endorsed symptoms of memory loss (corroborated by a close informant), exhibited objective decline from previous performance on neuropsychological tests sensitive to memory, and met published criteria for MCI. 1 MCI was first suspected based on collected study data, and such individuals were then invited to undergo a clinical neurological evaluation (RJC) that included standard laboratory and radiological assessments, after which a formal diagnosis was made and provided to the individual.
Members of the Arizona APOE Cohort who were administered the NEO-PI-R two or more times were considered for study inclusion. Individuals diagnosed with incident amnestic MCI who underwent the NEO-PI-R before developing MCI as well as at the time of MCI diagnosis were identified as MCI transitioners. The youngest MCI transitioner was aged 54 at the time of first NEO-PI-R administration, so a lower age cut-off of 50 at the time of the initial NEO-PI-R administration was chosen for the control group. Nontransitioners who took the NEO-PI-R serially but did not develop a cognitive disorder were included as controls. The first and last time each member took the NEO-PI-R, typically the first and second or third, were used to evaluate change in NEO-PI-R factor and facet scores.
Neuropsychological Assessment
A previously described comprehensive neuropsychological battery was administered every 2 years 25 and is summarized in Table 1 . Personality was assessed using the NEO-PI-R, which defines personality according to five factors: neuroticism, extraversion, openness, agreeableness, and conscientiousness. 22 It was added to our battery in 2006 and repeated on alternate visits (~every 4 years). Brief operational definitions of these five factors are as follows (adapted from 26 ); neuroticism is a tendency to feel anxiety and other negative emotions, extraversion is a tendency to be outgoing and lead in social contexts, openness is a tendency to be receptive to new ideas and experiences, agreeableness is a tendency to be trusting and deferential, and conscientiousness is a tendency to be organized and rule abiding. Each factor comprises six facets. For example, the six facets of the neuroticism factor all reflect reactivity to stress and include the tendency to experience anxiety, anger, depression, and self-consciousness; the ability to resist temptations and cravings (impulsivity); and a general ability to manage stress (vulnerability). 22 The NEO-PI-R is designed to measure personality traits and not psychological abnormality. The scores on the domain and facet scales represent how much of that particular trait an individual holds and do not imply clinical diagnosis or disorder. Therefore, our neuropsychological battery also includes measures of psychopathology (Table 1) , including (in addition to the Ham-D, which we use as a screening measure) the Beck Depression Inventory, the Geriatric Depression Scale (GDS), and the Personality Assessment Inventory (PAI). In contrast to the NEO-PI-R, the PAI is designed to measure clinically significant levels of symptomatology related to "clinical diagnosis, treatment planning and screening for psychopathology" (PAI manual page 5). It was not designed to measure the domains of normal personality. 27 
Statistical Analysis
Baseline demographic characteristics, NEO-PI-R scores, and other neuropsychological scores at the time of the first NEO-PI-R administration were summarized within the groups using means and 95% confidence intervals (CIs) or relative frequencies and compared between groups using t-tests and chi-square tests. NEO-PI-R change scores were computed as the score at last NEO-PI-R administration minus the score at the first administration. PAI change scores were similarly computed and were derived from the same administrations as the first and last NEO-PI-R administrations. NEO-PI-R and PAI change scores were compared between groups using t-tests. To assess withinsubject change, the percentage of subjects meeting various thresholds for meaningful change (5-point increase in Neuroticism or 5-point decline in Openness) of the groups was compared using chi-square tests. In a subsequent analysis to adjust for potential differences between groups in time between administrations, scores at the last visit were compared, adjusting for score at the first visit and time interval between administrations using analysis of covariance. To supplement primary univariate and multivariate statistical testing, a novel graphical approach using [a multisectional fishbone plot] displays NEO-PI-R domain and subdomain effect sizes. P ≤ .05 was considered statistically significant. Statistical analysis was conducted using SAS version 9 (SAS Institute, Inc., Cary, NC).
RESULTS
Two hundred seventy-seven members of the Arizona APOE Cohort met inclusion criteria, of whom 25 had incident MCI and 252 were nontransitioning controls. Subject characteristics at baseline are summarized in Table 2 . MCI transitioners were more likely to have the APOE e4 gene (80%) than nontransitioners (38.1%) (P < .001), but there was no difference in mean age (62.9, 95% CI = 62.1-63.8), education (16.1 years, 95% CI = 15.8-16.3 years), race and ethnicity (83.4% non-Hispanic white), sex (67.9% female), mean number of NEO-PI-R administrations (2.3, 95% CI = 2.3-2.4), or interval between first and last NEO-PI-R administration (78.9 months, 95% CI = 76.2-81.7 months) ( Table 2 ). Baseline scores did not differ between MCI transitioners and nontransitioners on any personality (NEO-PI-R factor and facet scores) or behavioral (PAI, Ham-D, Beck, GDS) measure. Neuropsychological and behavioral test performances at baseline, summarized in Supplementary Tables S1 and S2 , were normal, although the MCI transitioner group had lower scores on memory-related measures such as the Rey Auditory Verbal Learning Test Long-Term Memory (7.0, 95% CI = 5.8-8.2 vs 9.9, 95% CI = 9.5-10.3, P < .001).
Longitudinally, MCI transitioners had greater decline on multiple neuropsychological measures (as expected), particularly in the domains of memory and executive skills, than nontransitioners (Supplementary Table S1 ). NEO-PI-R changes are summarized in Figure 1 and Table 3 . At the group level, neuroticism T-scores increased more in MCI transitioners (2.9, 95% CI = 0.9-4.9) than in nontransitioners (0, 95% CI = À0.7-0.7) (P = .02), and openness decreased more in MCI transitioners (À4.8, 95% CI = À7.3 to À2.4] than in nontransitioners(À1.0, 95% CI = À1.6 to À0.4) (P < .001). Facet scores that worsened more in MCI transitioners than nontransitioners included the neuroticism facet score of depression (4.6, 95% CI = 1.7, 7.4 vs À0.2, 95% CI = À1.1, 0.6, P < .001) and the openness facet scores of activity (À4.6, 95% CI = À7.5 to À1.7 vs À1.1, 95% CI = À2.0 to À0.2, P = .02), aesthetics (À3.8, 95% CI = À7.0 to À0.6 vs À0.6, 95% CI = À1.4-0.1, P = .01), ideas (À3.6, 95% CI = À6.2 to À1.0 vs À0.8, 95% CI = À1.5-0.0, P = .03), and values (À5.1, 95% CI = À7.3 to À2.8 vs À0.5, 95% CI = À1.4-0.3, P = .002). Adjusting for length of time between NEO-PI-R administrations did not change these results. At the individual level, neuroticism T-scores increased by more than 5 points in 40% of transitioners and 18.3% of nontransitioners (P = .01), and openness T-score declined by more than 5 points in 48% of transitioners and 21.4% of nontransitioners (P = .003).
Concurrent clinically insignificant but statistically significant changes in behavioral scores revealed greater worsening in MCI transitioners than in nontransitioners, including measures of depression (PAI-clinical-depression: 4.2-95% CI = 1.3-7.1 vs 0.3, 95% CI = À0.8-1.3, 
DISCUSSION
This is the first study to demonstrate that changes in personality, including increasing neuroticism and decreasing openness, coincide with the transition from preclinical AD to incident MCI, with concomitant subclinical changes in behavioral measures of somatization, depression, anxiety, irritability, and aggression. Our findings are based upon longitudinal observations over more than 7 years before the transition point of incident MCI using the criterion standard personality measure, the NEO-PI-R, and are derived directly from participant responses rather than proxy estimates. There were no differences in baseline personality or behavioral scores that might otherwise have suggested a predisposition to these negative changes, consistent with the hypothesis that these changes were intrinsic to the disease process itself. These changes were identified at the same time that neuropsychological performance declined to the MCI level yet documented before a diagnosis of MCI was communicated to the participants, so they do not represent a reaction to diagnosis or a complication of treatment. All previous studies have relied upon informant recollections of the person's premorbid personality, and only approximately half used the 5-factor model. With few exceptions, participants had established dementia, which risks biasing retrospective estimates of presymptomatic functioning and possibly overestimating the degree of personality (vs frank behavioral) change. Only two studies have examined a similar period of transition. One used a semistructured interview and found no differences between 10 individuals transitioning from normal to MCI over the course of 3 years and controls. 20 Another found that individuals with preclinical AD experienced more personality changes than normal nontransitioners according to the Blessed Dementia Scale, including greater rigidity, apathy, and egocentricity and impaired emotional control. 21 Six previous studies used the NEO-PI 9,11,14,16 or NEO-PI-R, 19 all in individuals with established dementia, and all concluded that neuroticism increased, and extraversion, openness, and conscientiousness decreased with dementia. One study 11 found that agreeableness declined as well. Another 4 studies 7, 8, 15, 18 used the Brooks McKinlay Personality Inventory, 28 in which informants rate 18 dichotomized descriptors, and these also found a high frequency of change from the predementia to the postdementia state. Studies in which informants used the Blessed Dementia Scale 29 or Cambridge Mental Disorders of the Elderly Examination 30 also found reductions in interest, activity, and cognitive flexibility. 10, 17, 21 We have previously shown that memory decline is detectable preclinically, roughly 10 to 15 years before expected symptomatic onset, 25, 31 and that that personality affects longitudinal cognitive trajectories in a normal aging population. 32 Neuroticism and other personality factors do not change simply as a function of aging but are detectable within the context of symptomatic AD at its earliest clinical stage, and unlike preclinical memory decline, there is no preclinical escalation in depression scores before the symptomatic transition to MCI. 33 Thus, our current findings are consistent with a model in which personality changes follow memory decline during the transitional period and precede clinically symptomatic behavioral disorders that do not (usually) emerge until later in MCI and early dementia.
Behavioral symptoms pose major therapeutic challenges during the course of disease progression, and those b Analysis of covariance adjusted for first NEO-PI-R score and time interval P ≤ .05. All significant differences indicate greater worsening in MCI transitioners than nontransitioners.
that are severe enough to prompt pharmacotherapeutic intervention are not rare. For example, in a large Department of Veterans Affairs study, 17.7% of individuals with dementia in 1999 were taking antipsychotic drugs, and although their use has been declining in the United States and elsewhere since a 2006 Food and Drug Administration black box warning, 34 the prevalence of psychotropic use in Finland in 2011 was 45.0% to 47.9%. 35 In France, antidepressant use in individuals with dementia increased from 26% in 2010 to 31% in 2014. 36 Despite their widespread use, psychotropic agents have been found to be of inconsistent or no benefit in individuals with dementia 37 and to be associated with significant adverse outcomes. 38 It has been reported that neuroticism, as estimated from informant ratings of individuals with AD, was predictive of depressive symptoms in a cohort or 410 individuals with AD followed over 4 years. 39 If we can correlate early-stage personality changes with behavioral outcomes, it may be possible to prevent adverse behavioral outcomes. Caregivers and even individuals with dementia at these early stages may be alerted to impending behavioral risks, allowing for earlier life plans (e.g., medical proxies, wills) and potential prevention strategies. Clinical trials will be needed to assess the efficacy of any prevention therapies, including pharmacological and nonpharmacological interventions.
The neurobiology of personality is poorly understood. Structural 40 and functional 41 MRI studies of individuals with MCI have shown alterations in frontotemporal cortices that have been associated with behavioral disturbances, and we found concomitant cognitive changes not only in memory, but also in executive skills (which are not seen before MCI transition 42 ) during the MCI transition referable to these anatomical regions. Further work is needed to determine whether greater executive decline portends future behavioral impairment, because they share similar anatomical substrates. Chronic stress has itself been associated with poor functional integration of limbic networks, 43 smaller gray matter volumes in frontostriatal regions, 44 and a variety of functional and structural changes in prefrontal and hippocampal regions, 45 possibly predisposing stress-prone individuals to earlier personality changes and subsequent behavioral disturbances. Previous work has shown that personality factors influence cognitive aging trajectories 32 and risk of MCI and AD 46 and support the hypothesis that lifestyle choices that personality influences can affect cognitive outcomes, plausibly through modifiable cerebrovascular components of cognitive decline and dementia. 47 It is less clear whether there is an independent effect of personality on AD itself, but whether or not personality affects neuropathology, neuropathology can affect personality. Even at the earliest stage of symptomatic transition illustrated in this study, personality factors start to change in a way that one could expect to foster behavioral problems, and behavioral symptoms have been shown to be highly prevalent in individuals with established MCI and have included, congruent with our findings, depression, apathy, irritability, and anxiety most frequently. 48 A limitation of our study is the lack of neuropathological or biomarker evidence of AD neuropathology as the underlying cause of MCI in our participants. To address this, we used APOE ɛ4 as a proxy and inferred that MCI in APOE ɛ4 carriers reflects underlying AD because previous research has shown that ɛ4 is a strong predictor of clinical progression to AD in individuals with MCI, 49 and the positive predictive value of APOE ɛ4 for AD in a neuropathological series was 97%. 50 Another limitation is the small number of MCI transitioners who were administered the NEO-PI-R serially. Before our findings can be generalized, replication in other cohorts will be needed, although as our study progresses, we will be able to add to these numbers and identify behavioral outcomes to correlate with NEO-PI-R scores.
In summary, personality changes occur early in the clinical course of AD; are characterized by greater neuroticism and less openness; and coincide with subtle, clinically insignificant behavioral changes that qualitatively mirror and anticipate the clinically severe behavioral problems that often complicate dementia care. Further research is needed to determine whether earlier identification of predisposing personality changes might facilitate earlier, safer, more effective treatment or even prevention of behavioral disorders in individuals with AD.
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